02.08.24 -- Novo Acquires Catalent, Shakes Up Outsourcing World

Why is Professor Thomas Rademacher’s U.K.-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil.

The COVID-era guidance is designed to help manufacturers make container closure system changes quickly when facing supply constraints. It may be useful when evaluating risks beyond the pandemic.

Learn how a stage-gate approach to technology transfer and biomanufacturing can help to mitigate risk while shortening cycle times throughout the project life cycle.

Innovative solutions allow you to conceptualize and implement accelerated paths to compress processes while minimizing risk and ensuring product quality.

The biopharmaceutical industry is focused on maximizing the effectiveness of early-stage candidate assessments to predict a molecule’s chances of success before investing heavily in that molecule.

Assessing crystallinity is crucial as drug product stability may be seriously compromised if mannitol completes crystallization during storage rather than during the freezing or annealing step in the lyophilization process.

Improving your ADC’s chance of clinical success requires an understanding of what potential obstacles lie ahead and what capabilities and expertise are necessary to overcome them.

Review four key factors for improving on-time delivery when outsourcing drug product manufacturing and discover how investing in building a solid relationship with your CDMO improves timelines.

Over the years we’ve learned invaluable lessons in the development of biologics and share our project management experience to support our customers’ drug strategies.

Learn how an advanced conjugation technology can provide a more uniform DAR profile, enhanced linker stability, and improved pharmacokinetic properties, paving the way for more efficacious ADCs.

We offer biologics contract manufacturing using state-of-the-art technologies to develop and manufacture clinical trial materials for viral vaccines, gene and immune therapeutics, oncolytic viruses, and recombinant proteins.